1-3 of 3
Khuda D. Khan, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

John C. Byrd, MD, Ian W. Flinn, MD, Khuda D. Khan, MD, Thomas J. Kipps, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Serge Guzy, PhD, Sanela Bilic, PharmD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD, Susan O’Brien, MD
Journal: Blood
Blood (2006) 108 (11): 2837.
https://doi.org/10.1182/blood.V108.11.2837.2837
Published: 2006
Journal Articles

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.

Khuda D. Khan, MD, PhD, Susan O’Brien, MD, Kanti R. Rai, MD, Jennifer R. Brown, MD, PhD, Perry Cook, MD, Anne Marie Maddox, MD, Alison M. Duarte, MPH, Eric J. Haltom, Margaret J. Uprichard, PharmD
Journal: Blood
Blood (2005) 106 (11): 2125.
https://doi.org/10.1182/blood.V106.11.2125.2125
Published: 2005
Journal Articles

Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.

Stephen M. Ansell, MD, PhD, John C. Byrd, MD, Steven M. Horwitz, MD, Peter Borchmann, MD, Andreas Engert, MD, Roger Strair, MD, Khuda D. Khan, MD, Steven A. Fischkoff, MD, Michael Yellin, MD
Journal: Blood
Blood (2004) 104 (11): 2636.
https://doi.org/10.1182/blood.V104.11.2636.2636
Published: 2004